Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Accumulated Expenses: 2016-2025

Historic Accumulated Expenses for Akebia Therapeutics (AKBA) over the last 10 years, with Sep 2025 value amounting to $106.4 million.

  • Akebia Therapeutics' Accumulated Expenses rose 103.81% to $106.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $106.4 million, marking a year-over-year increase of 103.81%. This contributed to the annual value of $63.5 million for FY2024, which is 6.31% down from last year.
  • Akebia Therapeutics' Accumulated Expenses amounted to $106.4 million in Q3 2025, which was up 16.16% from $91.6 million recorded in Q2 2025.
  • Akebia Therapeutics' Accumulated Expenses' 5-year high stood at $144.7 million during Q3 2021, with a 5-year trough of $51.1 million in Q1 2023.
  • Over the past 3 years, Akebia Therapeutics' median Accumulated Expenses value was $62.7 million (recorded in 2023), while the average stood at $66.4 million.
  • Per our database at Business Quant, Akebia Therapeutics' Accumulated Expenses tumbled by 55.29% in 2023 and then surged by 103.81% in 2025.
  • Quarterly analysis of 5 years shows Akebia Therapeutics' Accumulated Expenses stood at $109.0 million in 2021, then slumped by 30.49% to $75.8 million in 2022, then fell by 10.61% to $67.7 million in 2023, then dropped by 6.31% to $63.5 million in 2024, then spiked by 103.81% to $106.4 million in 2025.
  • Its last three reported values are $106.4 million in Q3 2025, $91.6 million for Q2 2025, and $71.3 million during Q1 2025.